High-risk multiple myeloma: Integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment
Solimando AG, Da Via MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Tascon JD, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortuem KM, Beilhack A, Racanelli V, Vacca A, Einsele H (2019)
Publication Type: Journal article, Review article
Publication year: 2019
Journal
Book Volume: 8
Article Number: 997
Journal Issue: 7
DOI: 10.3390/jcm8070997
Abstract
Multiple myeloma (MM) is a genetically heterogeneous disease that includes a subgroup of 10–15% of patients facing dismal survival despite the most intensive treatment. Despite improvements in biological knowledge, MM is still an incurable neoplasia, and therapeutic options able to overcome the relapsing/refractory behavior represent an unmet clinical need. The aim of this review is to provide an integrated clinical and biological overview of high-risk MM, discussing novel therapeutic perspectives, targeting the neoplastic clone and its microenvironment. The dissection of the molecular determinants of the aggressive phenotypes and drug-resistance can foster a better tailored clinical management of the high-risk profile and therapy-refractoriness. Among the current clinical difficulties in MM, patients’ management by manipulating the tumor niche represents a major challenge. The angiogenesis and the stromal infiltrate constitute pivotal mechanisms of a mutual collaboration between MM and the non-tumoral counterpart. Immuno-modulatory and anti-angiogenic therapy hold great efficacy, but variable and unpredictable responses in high-risk MM. The comprehensive understanding of the genetic heterogeneity and MM high-risk ecosystem enforce a systematic bench-to-bedside approach. Here, we provide a broad outlook of novel druggable targets. We also summarize the existing multi-omics-based risk profiling tools, in order to better select candidates for dual immune/vasculogenesis targeting.
Involved external institutions
University of Bari Aldo Moro / Università degli Studi di Bari Aldo Moro
Italy (IT)
Universitätsklinikum Heidelberg
Germany (DE)
Murgia Hospital Fabio Perinei / Ospedale della Murgia Fabio Perinei
Italy (IT)
Italy (IT)
Universitätsklinikum Heidelberg
Germany (DE)
Murgia Hospital Fabio Perinei / Ospedale della Murgia Fabio Perinei
Italy (IT)
How to cite
APA:
Solimando, A.G., Da Via, M.C., Cicco, S., Leone, P., Di Lernia, G., Giannico, D.,... Einsele, H. (2019). High-risk multiple myeloma: Integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment. Journal of Clinical Medicine, 8(7). https://doi.org/10.3390/jcm8070997
MLA:
Solimando, Antonio Giovanni, et al. "High-risk multiple myeloma: Integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment." Journal of Clinical Medicine 8.7 (2019).
BibTeX: Download